MarketCap
Facebook
X
TelegramAnnual report 2022
added 08-30-2022
Genetic Technologies Limited Market Cap 2011-2026 | GENE
As of January 01, 2026 Genetic Technologies Limited has a market cap of $ 7.1 B
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap Genetic Technologies Limited
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 9.22 B | 17.1 B | 16.6 B | 11.7 M | 19.8 M | 12.9 M | 26 M | 24.4 M | 17.4 M | 40.1 M | 57.6 M | 81.5 M |
All numbers in AUD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 17.1 B | 11.7 M | 3.6 B |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Diagnostics research industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Akumin
AKU
|
75.1 M | - | -17.87 % | $ 25.9 M |  Canada |
|
Centogene N.V.
CNTG
|
221 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Accelerate Diagnostics
AXDX
|
40.3 M | - | -61.36 % | $ 2.46 M |  USA |
 |
Brainsway Ltd.
BWAY
|
240 M | $ 19.02 | 0.21 % | $ 99.4 M |  Israel |
 |
Co-Diagnostics
CODX
|
34.9 M | $ 0.17 | -6.7 % | $ 4.99 M | USA |
 |
Burning Rock Biotech Limited
BNR
|
2.95 B | $ 20.15 | -2.3 % | $ 217 M |  China |
 |
Danaher Corporation
DHR
|
152 B | $ 228.92 | -0.76 % | $ 167 B | USA |
 |
Biocept
BIOC
|
5.93 M | - | -13.05 % | $ 7.29 M | USA |
 |
Chembio Diagnostics
CEMI
|
12.6 M | - | 0.22 % | $ 16.8 M | USA |
 |
DexCom
DXCM
|
48.8 B | $ 66.37 | -1.03 % | $ 25.6 B | USA |
 |
BioNano Genomics
BNGO
|
3.55 M | $ 1.53 | 2.0 % | $ 1.94 M | USA |
 |
Castle Biosciences
CSTL
|
709 M | $ 38.9 | -1.04 % | $ 1.08 B | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
421 M | - | - | $ 562 M |  Britain |
 |
DermTech
DMTK
|
42.4 M | - | -11.32 % | $ 2.94 M | USA |
 |
DarioHealth Corp.
DRIO
|
43.4 M | $ 11.38 | 6.36 % | $ 323 M | Israel |
 |
IQVIA Holdings
IQV
|
35.7 B | $ 225.41 | -1.0 % | $ 40.9 B | USA |
 |
Enzo Biochem
ENZ
|
57.5 K | - | -8.98 % | $ 14.8 K | USA |
 |
Exact Sciences Corporation
EXAS
|
9.32 B | $ 101.56 | -0.33 % | $ 18.8 B | USA |
 |
Fulgent Genetics
FLGT
|
467 M | $ 26.27 | -0.83 % | $ 794 M | USA |
 |
Global Cord Blood Corporation
CO
|
243 M | - | - | $ 399 M | China |
 |
Fluidigm Corporation
FLDM
|
481 M | - | 1.08 % | $ 308 M | USA |
 |
Genetron Holdings Limited
GTH
|
1.54 B | - | 0.12 % | $ 80.1 M | China |
 |
PRA Health Sciences, Inc.
PRAH
|
7.87 B | - | - | $ 10.7 B | USA |
 |
Myriad Genetics
MYGN
|
973 M | $ 6.15 | -0.32 % | $ 557 M | USA |
 |
CareDx, Inc
CDNA
|
521 M | $ 18.84 | -1.21 % | $ 1.01 B | USA |
 |
NeoGenomics
NEO
|
1.53 B | $ 11.76 | -3.84 % | $ 1.49 B | USA |
 |
Celcuity
CELC
|
399 M | $ 99.74 | -0.18 % | $ 3.93 B | USA |
 |
National Research Corporation
NRC
|
1.01 B | $ 18.77 | 0.64 % | $ 461 M | USA |
 |
Anixa Biosciences
ANIX
|
70.8 K | $ 3.12 | - | $ 99.5 K | USA |
 |
Precipio
PRPO
|
8.7 M | $ 22.98 | -1.84 % | $ 29.8 M | USA |
 |
Personalis
PSNL
|
254 M | $ 7.96 | -0.13 % | $ 472 M | USA |
 |
Heska Corporation
HSKA
|
844 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
2.99 M | - | -20.0 % | $ 1.06 M | USA |
 |
Guardant Health
GH
|
5.84 B | $ 102.14 | 1.53 % | $ 12.5 B | USA |
 |
Aspira Women's Health
AWH
|
45.4 M | - | -6.19 % | $ 10.5 M | USA |
 |
ENDRA Life Sciences
NDRA
|
2.2 M | $ 4.53 | -4.83 % | $ 2.43 M | USA |
 |
Soleno Therapeutics
SLNO
|
1.96 B | $ 46.3 | 0.02 % | $ 1.86 B | USA |
 |
Illumina
ILMN
|
16.4 B | $ 131.16 | -1.2 % | $ 20.9 B | USA |
 |
Charles River Laboratories International
CRL
|
8.54 B | $ 199.48 | -1.24 % | $ 10.2 B | USA |
 |
Thermo Fisher Scientific
TMO
|
206 B | $ 579.45 | -0.69 % | $ 221 B | USA |
 |
Trinity Biotech plc
TRIB
|
120 M | $ 0.79 | -3.54 % | $ 61.9 M |  Irlanda |
 |
Quest Diagnostics Incorporated
DGX
|
19.1 B | $ 173.53 | -1.12 % | $ 19.3 B | USA |
|
Biodesix
BDSX
|
92.1 M | $ 6.8 | 1.19 % | $ 882 M | USA |
 |
Motus GI Holdings
MOTS
|
990 K | - | -34.28 % | $ 263 K | Israel |
 |
Laboratory Corporation of America Holdings
LH
|
21.1 B | $ 250.88 | -0.87 % | $ 21 B | USA |
 |
Twist Bioscience Corporation
TWST
|
1.56 B | $ 31.72 | -1.34 % | $ 1.9 B | USA |
 |
ICON Public Limited Company
ICLR
|
16.6 B | $ 182.22 | -0.43 % | $ 15 B | Irlanda |
 |
IDEXX Laboratories
IDXX
|
37.7 B | $ 676.53 | -0.85 % | $ 55.8 B | USA |
 |
Lantheus Holdings
LNTH
|
6.47 B | $ 66.55 | -0.91 % | $ 4.61 B | USA |